Korean J Hematol.  2010 Sep;45(3):143-144. 10.5045/kjh.2010.45.3.143.

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?

• Lee JJ

• KMID: 2252048
• DOI: http://doi.org/10.5045/kjh.2010.45.3.143

Abstract

No abstract available.

MeSH Terms

Humans
Syndecan-1
Syndecan-1

Reference

1. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23:3412–3420. PMID: 15809451.

2. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84:1095–1110. PMID: 19955246.

3. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010; 149:334–351. PMID: 20201947.

4. Scudla V, Pika T, Budikova M, et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma. 2010; 57:102–110. PMID: 20099972.

5. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002; 100:610–617. PMID: 12091355.

6. Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000; 95:388–392. PMID: 10627439.

7. Oguri K, Okayama M. Can syndecan-1 become a prognostic factor in solid tumors? J Gastroenterol. 2004; 39:197–199. PMID: 15074308.

8. Kim JM, Lee JA, Cho IS, Ihm CH. Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study. Korean J Hematol. 2010; 45:115–119.

9. Lee JH, Lee DS, Lee JJ, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean multiple myeloma working party. Int J Hematol. 2010; 92:52–57. PMID: 20544403.

10. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009; 23:1941–1956. PMID: 19657360.